Skip to main content
. 2022 Aug 30;12:939118. doi: 10.3389/fonc.2022.939118

Figure 1.

Figure 1

Percent tumor response by patient and dose (A) and by plasma erlotinib measured by LC/MS/MS analysis (B). N = 19; 10 patients received erlotinib at 300 mg PO daily (cyan in panel A and panel B) and 9 received erlotinib 150 mg PO daily (pink in panel A and panel B).